medigraphic.com

2002, Number 3

<< Back

Rev Fac Med UNAM 2002; 45 (3)

The National Vaccination Program: pride of Mexico

Santos JI

Language: Spanish
References: 17
Page: 142-153
PDF size: 286.61 Kb.


ABSTRACT

Following a brief yet illuminating history of vaccination around the world and in Mexico, there is a description of the exemplary trip made by Balmis from Spain to Cuba, Mexico, Guatemala and the Philippines. The creation of the National Bacteriology Institute that began the production of the small pox vaccine, and the founding of the National Institute of Virology which started producing the anti-poliomyelitic trivalent vaccine, under the supervision of Dr. Albert Sabin, improved the production of the antirabies vaccine and tetanus toxoid, and finally produced the rubella vaccine using the Edmonston-Zagreb strain.
In 1990, Mexico was one of the seven countries in the world to be self-sufficient in the production of biologicals and, despite a brief lapse in which Mexico dropped from this group, the BIRMEX project initiated in 1999 gave priority to continue the consolidation process.
Since 1991, the Universal Vaccination Program has been in operation achieving almost all of its objectives: eradication of poliomyelitis, diphtheria, rubella and neonatal tetanus: control of pertussis and severe forms of tuberculosis. In addition, the program includes important aims such as the strengthening of epidemiologic surveillance through identification, notification and immediate control of cases and outbreaks, promotion and education for health and community participation, as well as following the “vaccination card”. Since 1983, national vaccination days have been established, and since 1993, National Health Weeks have been enlarged with vaccination against rubella shows the Vaccination Program to be a qualified success, thanks to he good use of modern technology, political will and society´s spirit of solidarity.


REFERENCES

  1. Camacho-AML, Morales-Romo A, Calvo A, Díaz-Ortega JL, Valdespino-Gómez JL, González-Velásquez MS, et al. Evaluación de la cadena de frío en los Días Nacionales de Vacunación antipoliomielítica. México, 1987-1988. Salud Pública de Méx. 1990; 32: 43-51.

  2. Camacho-Amor ML, Valdespino-Gómez JL, Ayala-González M, Días-Ortega JL, González-Velázquez MS, Morales-Romo A, Chávez-San Juan R. Evaluación de la cadena del frío y seguimiento de la potencia de la vacuna antisarampión en campo. Bol Med Hosp Infant Mex 1990; 47: 506-511.

  3. Carrasco TR, Dinstrans SR, Montaldo, et al. Cadena de frío del Programa Ampliado de Inmunizaciones. Bol Of Sanit Panam 1983; 94: 37-45.

  4. Consejo Nacional de Vacunación. Programa de Vacunación Universal 1995-2000. México, 1995.

  5. Consejo Nacional de Vacunación. Cadena de Frío. Manual de Procedimientos Técnicos. México, 1999.

  6. Chen RT, De Stefano F. Vaccine adverse events: causal or coincidental? Lancet 1998; 351: 611-612.

  7. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, Wassilak SG. The vaccine adverse event reporting system (VAERS). Vaccine 1994; 12: 542-550.

  8. Cheyne J. Mejora de la Cadena de frío para las vacunas. Foro Mundial de la Salud 1982; 3: 500-504.

  9. Fine PEM. Safety of measles vaccines. In: Kurstak E. Measles and poliomyelitis. Springer-Verlag, Australia. 1993; 63-73.

  10. Galazka A, Milstein J, Zaffran M. Thermostability of vaccines. World Health Organization. 1998. WHO/GPV/98.07.

  11. Griffin MR, Ray WA, Livengood JR. Risk of sudden infant death syndrome after immunization with the diphteria-tetanus-pertussis vaccine. N Engl J Med 1988; 319: 618-623.

  12. Nkowane BM, Wassilak SGF, Orenstein WA, Bart K, Schonberger LB, Hinman AR, Kew OM. Vaccine-associated paralytic poliomyelitis. United States: 1973 trough 1984. JAMA 1987; 257: 1335-1340.

  13. Organización Panamericana de la Salud. Inmunizaciones. Información para la acción Pub Cient No. 472, Washington, 1984.

  14. Pral MM, Woe Fang FL, Rizo E. Potency control of live attenuated vaccines against measles used in children vaccinations in the state of São Paulo, Brazil (1976-1980). Rev Inst Med Trop São Paulo. 1982; 24: 1-5.

  15. Vacunación: Garantía para la Infancia. Serie Cuadernos de Salud, SSA, México, 1994.

  16. Silveira TR, da Fonseca JC, Rivera L, Fay OH, Tapia R, Santos JI, Urdeneta E, Costa Clemens SA. Hepatitis B seroprevalence in Latin América. Rev Panam Salud Publica 1999; 6(6): 378-383.

  17. Maddrey WC. Hepatitis B-an important public health issue. Clin Lab 2001; 47(1): 51-5.




2020     |     www.medigraphic.com